Old Web
English
Sign In
Acemap
>
authorDetail
>
Laurie S. Kane-Carson
Laurie S. Kane-Carson
GlaxoSmithKline
MAPK/ERK pathway
Melanoma
Biology
Dabrafenib
Cell growth
3
Papers
291
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
2013
PLOS ONE
Alastair J. King
Marc R. Arnone
Maureen R. Bleam
Katherine G. Moss
Jingsong Yang
Kelly E. Fedorowicz
Kimberly N. Smitheman
Joseph A. Erhardt
Angela Hughes-Earle
Laurie S. Kane-Carson
Robert H. Sinnamon
Hongwei Qi
Tara Renae Rheault
David E. Uehling
Sylvie Laquerre
Show All
Source
Cite
Save
Citations (127)
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.
2013
ACS Medicinal Chemistry Letters
Tara Renae Rheault
John Stellwagen
George Adjabeng
Keith Hornberger
Kimberly G. Petrov
Alex G. Waterson
Scott Howard Dickerson
Robert A. Mook
Sylvie Laquerre
Alastair J. King
Olivia W. Rossanese
Marc R. Arnone
Kimberly N. Smitheman
Laurie S. Kane-Carson
Chao Han
Ganesh S. Moorthy
Katherine G. Moss
David E. Uehling
Show All
Source
Cite
Save
Citations (120)
Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation
2009
Molecular Cancer Therapeutics
Sylvie Laquerre
Marc R. Arnone
Katherine G. Moss
Jingsong Yang
Kelly E. Fisher
Laurie S. Kane-Carson
Kimberly N. Smitheman
Jessica Ward
Bradley Heidrich
Tara Renae Rheault
George Adjabeng
Keith Hornberger
John Stellwagen
Alex G. Waterson
Chao Han
Robert A. Mook
David E. Uehling
Alastair J. King
Show All
Source
Cite
Save
Citations (44)
1